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Preface
In this study, the costs and quality of life effects of Filgrastim® treatment (r-met-HuG-
CSF) in patients with persistent chronic rhinosinusitis were assessed. This economic
evaluation was performed alongside a double blind randomized placebo controlled
clinical trial in three Dutch university centres. The results of the cost analysis and the
quality of life study are described separately in this report. This was done to emphasize
the merits of both studies most clearly.
Beyond the clinical outcome parameters, quality of life was seen as an important
outcome measure on it's own because the clinical symptoms of the disease were never
expected to disappear entirely after the administration of Filgrastim®. It nevertheless
seemed plausible that the symptoms should be reduced significantly, which presumably
would be translated in the quality of life as reported by the patients themselves.
The cost analysis not only contains a comparison of the costs in the placebo group with
the costs in the Filgrastim® group. Additionaly, as the trial costs were expected to be
driven particularly by protocollary diagnostic tests and outpatient visits, a comparison of
the costs in the trial interval with the costs of a regular treatment was made.
This manuscript is meant as a detailed research report. Journal articles resulting from this
research will follow.
Rotterdam, August 2000
Michel van Agthoven
Jan J.V. Busschbach
Carin A. Uyl-de Groot
Summary
This is the first report of the double blind randomized clinical trial, in which we
investigated the influence of Filgrastim® on the quality of life and treatment costs of
chronic sinusitis patients who did not respond to regular treatments.
The quality of life of 56 patients was assessed 5 times during the 24-week trial with the
EuroQol, the SF-36 and the McGill Pain questionnaire. We further controlled for
"responsiveness", based on clinical impression.
Direct medical and indirect non-medical costs per patient during the trial were analyzed,
based on data from clinical record forms and the hospital information system. We
further compared the direct medical costs to the costs of regular treatment.
The quality of life scores were all below population norm scores. Quality of life scores of
the Filgrastim® group suggested a better quality of life than the placebo group, although
none of the differences were statistically significant. There were indications that
controlling for responsiveness increased the power of the design.
The difference in costs between the trial groups were driven by the Filgrastim® costs
(Euro 4899). When Filgrastim® costs were neglected, no difference in costs remained.
Except for Filgrastim®, total direct costs summed up to Euro 2712 and the indirect
costs to Euro 582. Total direct costs of a 24-week regular treatment were three times
lower than the costs of the trial treatment.
While significantly increasing treatment costs, Filgrastim® administration does not lead
to a better quality of life of chronic sinusitis patients, although there were some
indications that it might be possible to determine a subpopulation in which the results
are better.
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Introduction
The interest in chronic rhinosinusitis in the past decade has been aimed primarily at
medical treatment of sinusitis before functional endoscopic sinus surgery (FESS) and
FESS and its outcomes. FESS aims at restoring the normal anatomical structures
enabling the diseased mucosa to repair. Little has been reported about possibilities in the
case of recurrent or persistent chronic rhinosinusitis in patients who do not respond to
the conventional treatments. In the protection of the paranasal sinusses against bacterial
and fungal rhinosinusitis, neutrophils seem to play an important role (Dale & Hammond,
1988). The proliferation and differentiation of neutrophils is promoted by the
administration of human hematopoetic granulocyte colony stimulating factors (G-CSF).
In cancer patients, filgrastim (r-met-HuG-CSF) is currently administered to reduce
neutropenia induced by cytostatic therapy. A pilot study at the Erasmus University
Medical Centre Rotterdam showed that patients without known predisposing or
aggravating factors for persistent chronic rhinosinusitis, low neutrophil counts and
unsuccesful response to conventional treatments might benefit from filgrastim treatment.
In this double blind randomized clinical trial, the effects of filgrastim (r-met-HuG-CSF)
on the quality of life of patients with chronic sinusitis were investigated.
Quality of life was seen as an important outcome measure, since the bacterial infections
were not expected to disappear completely, but it nevertheless seemed plausible that the
effects of the infections would be reduced. The outcome measurement should therefore
be the quality of life as measured by a subjective response of the patients themselves.
This measurement has rarely been performed in chronic sinusitis, and it is a distinct
approach compared to usual clinical measurements. So far, quality of life measurements
in chronic sinusitis patients relied on the Rhinosinusitis Disability Index (Maune et al.,
1999) and the Chronic Sinusitis Survey Score (Glicklich & Hilinski, 1995; Gliklich &
Metson, 1995; Alsarraf et al., 1999). A disadvantage of these disease specific
questionnaires is that they do not allow for comparisons between different interventions
and patient groups, which complicates the interpretation of the effect size. Given the
high costs of filgrastim, an estimation of the effect size was seen as highly relevant in this
investigation. We therefore focused on generic quality of life questionnaires, which can
be compared to other health care programs. We therefore measured quality of life by
using the EuroQol, the SF-36 and the McGill Pain Questionnaire. Only the SF-36 has
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been used before in chronic sinusitis patients, but only to evaluate the effects of
endoscopic sinus surgery (Glicklich & Hilinski, 1995; Metson & Gliklich, 1998). A
problem associated with the use of a battery of generic questionnaires is the high number
of outcomes that have to be evaluated. This is especially true when multidimensional
questionnaires are used, like in this investigation. In that case a serious risk of chance
cumulation exists. For this reason, primary, secondary and explorative outcomes
measures were defined at forehand.
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Materials and methods
Patients and treatment
This study was performed as a double blind two-arm placebo controlled randomized
trial. Patients were registered at T-4 for a pre-treatment observation of 4 weeks before
being randomized. Between June 1995 and November 1997, 59 patients were
randomized in the trial at the Eramus Medical Centre Rotterdam (35), the University
Medcal Centre Utrecht (19) and the University Hospital Nijmegen (5). Only patients with
symptoms lasting for more than 6 months were included in order to cover the group of
severe chronic bacterial sinusitis patients. The included patients had been given all
conventional treatments, such as antibiotics, nasal decongestants, functional endoscopic
sinus surgery, frontal sinus surgery and Caldwell-Luc procedures, yet they still suffered
from their disease as the treatments were unsuccessful. Patients were included when no
indication for surgical interventions of any kind to improve the chronic sinusitis was
found.
After randomization (official study entry at T0), all patients were treated with a
combination of Ciprofloxacin 750mg once a day and Clindamycin 600 mg 3 times a day
for 14 days. Patients were randomized to Filgrastim 300 µg subcutaneously (s.c.) or
placebo s.c. once a day for the first 14 days (until T2) and for another 10 weeks (until T12)
with either Filgrastim 300 µg s.c. or placebo s.c. every two days. After this treatment
period, patients were followed for another 12 weeks until T24 (post treatment observation
period).
Patients were asked to complete quality of life questionnaires at trial inclusion (T-4), at
randomization (T0) and at T2, T4, T12 and T24. They were included in the quality of life
analyses if they returned at least one of the questionnaires of the period in which the
drug could be active (T2, T4 and T12).
Quality of life measurements
As quality of life measurements have not been performed often in chronic sinusitis
patients, a short description of each of the measurement instruments that we used is
reported. These multidimensional questionnaires yield a high number of outcomes. In
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order to control for the risk of chance cumulation, we categorized the outcomes into
"primary outcomes" and "secondary outcomes". The primary outcomes were those
outcomes which can be argued to have a contentual relationship with the problems
experienced by chronic rhinosinusitis patients.
Three quality of life measurement instruments were used in the current study: the SF-36
and the EuroQol, which are both generic questionnaires. A more domain specific
questionnaire used was the McGill Pain Questionnaire, as pain was considered to be an
important outcome.
SF-36 scores are measured on 9 subscales, which can be aggregated into 2 sum scores,
physical health and mental health (Ware et al., 1994). These two sum scores were used as
primary outcomes. Secondary outcomes were the 9 subscales, of which 5 seemed closely
related to chronic sinusitis: physical functioning, social functioning, physical role
functioning, vitality and pain. A pilot study preceding the current study showed that
chronic sinusitis patients scored well below the norm scores of the Dutch Population on
these 5 subscales. Of the remaining 4 subscales measured, the subscales “emotional role
functioning” and "mental health" do not have a contentual relation with chronic sinusitis
and were therefore used as secondary outcomes. The content of the subscale "general
health" was also measured by the EuroQol Visual Analogue Scale (EQVAS) and was
therefore not used as a primary outcome measure. The subscale "health transition" was
only part of the explorative analysis, because at forehand it was not clear at which
moment a notable change in health state would occur.
The EuroQol questionnaire, existing of two parts, is originally designed to estimate
utilities for the calculation of Quality Adjusted Life Years (Drummond et al., 1997). The
first part is a generic 5 dimensional questionnaire, the EQ-5D. This profile can be
transformed to a value given by the general public: the EQ-5Dindex (Dolan, 1997). This
societal value of the health state represents the societal perspective, which is the
preferred perspective in economic evaluation of health care (Hadorn, 1991; Drummond
et al., 1997; Gold et al., 1996). The second part of the EuroQol questionnaire is a visual
analogue scale, the EQvas. The EQvas represents the patient's judgement of his own health
state. This patient perspective is useful in clinical decision making without cost
considerations. In this study, both the societal and the patient perspective of the
EuroQol were used as primary outcome measures.
Since pain was considered to be a domain of special attention, the McGill Pain
Questionnaire (Melzack, 1975, 1987) was added. In this investigation, the Dutch
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translation (the MPQ-DLV) was used (Kloot et al., 1995; Verkes et al., 1989; Kloot &
Vertommen, 1989). The Pain Rating Index Total Score (PRI-T) was chosen as the
primary outcome score for this questionnaire. The PRI-T-score is the sum of the rank
values of the words "sensorial", "affective" and "evaluative" chosen by the patients. The
rating indexes of the subscales were defined as secondary outcomes.
Questionnaire timing
The patients completed questionnaires at T-4 (trial inclusion), at T0 (randomization), at T2
(dose of study medication was halved), at T4, at T12 (end of study medication) and at T24
(end of trial). The questionnaires were filled in at the day the clinician was visited or at
home at the prescribed date, if the patient could not visit the clinician at this date. At all
times, all questionnaires were administered, except the SF-36 at T2.
Three periods of interest were distinguished:
1. The period before randomization (T-4 and T0).
2. The period in which the drug can have an effect on the outcome parameters: T2, T4
and T12. At T2, the doses of the medication were halved by giving the treatment every
other day.
3. The period after the end of the treatment is represented by T24.
Covariates
During the data collection of this double blind trial, clinicians suspected that some of the
included patients could be labelled as less responsive to the drug than others. For
instance, after several surgical interventions, the amount of scar tissue and the changes in
anatomy might be so large that a restoration to a normal situation is impossible. Also,
some of these patients experience pain in any case, irrespective of therapy. Another
aspect may be that the patients profit socially from the illness, for instance in terms of
attention and respect. In an effort to control for these effects, the clinicians categorized
the patients into three groups: "probably not responsive", "not clear", and "probably
responsive". As part of the secondary analysis, this covariate was used in the analyses of
the primary outcome measures.
Quality of life in chronic rhinosinusitis
11
Missing values
Repeated measures are vulnerable for missing values or inadequate timing of the
administration of the questionnaires. If a measurement is missing or its timing is wrong,
the patient has to be removed from the analysis. Therefore, in the case of repeated
measurements, missing values are often interpolated (Beacon & Thompson, 1996;
Zwinderman, 1992). All interpolation algorithms make use of the assumption that the
missings occur independently of the dependent variable: "missing at random" (Maas &
Snijders, submitted). This means that missing values do not depend on the level of the
quality of life. It is therefore essential to investigate if it is reasonable to assume that the
missing occurred "at random". All missing values were discussed in a meeting with the
participating clinicians. During this meeting it was determined if a missing value could be
classified as "missing at random". If the missing value is "at random" or the number of
missings is small (Gillings & Koch (1991) suggest a maximum of 10%), interpolation
methods can be used. In this investigation four types of interpolation methods were
used.
1. Sometime it was possible to give an exact alternative, for instance for the variable
gender, age, etc.
2. The second method was the use of published algorithms when some items of a scale
are missing. Such an algorithm was used for the SF-36 (Ware et al., 1993). When a
patient marked two discreet alternatives instead of one (this can be the case in the
EuroQol and the SF-36), the worse alternative was chosen. In the case of a
continuous response variable, the mean of the two values was used.
3. Sometimes the patient completed the questionnaire some days later. If the delayed
response still made sense in relation to the event to which it relates, the delayed
response was used as a proxy. For instance, a delay of 10 days at T24 interferes only
little with the purpose of that particular measure, but a delay of 10 days at T2
interferes with measurement at T4.
4. In all other cases, the value was imputed using the expectation-maximization method
using the known variables of the specific measure as predictors (by using the
"Missing Value Analysis" in SPSS for Windows, release 9.0.0).
In all cases a statistical significance level of 5% was chosen.
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Results
59 patients were randomized in the trial, of which one was removed from the analysis at
T0, since this patient turned out to have cystic fibrosis. Characteristics of the remaining
58 patients are shown in Table 1. After having passed T0, two more patients were
removed (one quitted because of bone pain and the other was mistakenly randomized
before the bacterial infection was confirmed).
Table 1. Patient characeteristics at baseline (T0). Mean (standard deviation).
Patient characteristics filgrastim placebo P-value total
Number 27 31 0.694 58
Male 8 18 0.078 26
Female 19 13 0.377 32
Currently employed 14 16 0.809 30
Age 45 (10) 42 (11) 0.356 44 (10)
Work hours per week per working patient 33.0 (9.6) 35.7 (14.4) 0.552 34.4 (12.2)
Primary endpoints of the quality of life questionnaires of these patients at baseline are
presented in Table 2. From the reference values in this table and from the Figures 1 and
2, it can be seen that all scores on the primary end points are below the population
averages, which indicates an impaired quality of life in this patient group.
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All of the remaining 56 patients returned at least two of the questionnaires T2, T4 and T12.
Totally, 330 of the 336 distributed questionnaires were returned (98,2%). The number of
delayed responses was small and occured mostly at the end of the trial. Two patients had
difficulties reading the questionnaires, due to language problems. Of these patients, only
the scores of the simple to administer EQ-5D and EQvas were included in the analysis.
End points
In almost all primary end points, the scores of the filgrastim group suggested a better
quality of life than the placebo group. However, none of these differences were
significant. Figure 1 presents the development of the EQ-5Dindex.
None of the analyses of the secondary variables showed significant differences between
the placebo group and the filgrastim group. Including the covariant "responsiveness"
improved the power of the design at T2, T4 and T12: most p-values dropped.
Nevertheless, none of them dropped below 0,10.
All primary and secondary endpoints of each questionnaire are shown in Table 2.
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Figure 1. Scores of the study group on the EuroQol EQ-5D index compared to scores of the general
U.K. population (Kind et al., 1999).
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Figure 2. Mean scores of the study group on the SF-36 Physical Composite Score compared to scores of
the general U.S. population, of patients with chronic lung disease and of patients with chronic obstructive
pulmonary disease (COPD) (Ware et al., 1994).
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Discussion
In this randomized clinical trial 58 patients with chronic sinusitis were treated with
filgrastim or placebo. We tested the effects on several quality of life measures, including
the McGill Pain Questionnaire, The EuroQol and the SF-36. All scores were well below
the population norm scores, indicating a lower quality of life in this patient group. The
scores of the filgrastim group suggested a better quality of life than the placebo group,
but none of these differences were significant. We further controlled for
"responsiveness", an ordinal variable which was based on the clinical impression. This
covariate improved the power of the analysis, but it did not result in significant
differences between the filgrastim group and the placebo group.
The lack of significant results in this trial could be the result of an insensitivity of the
quality of life questionnaires for the effects of chronic sinusitis. However, this
explanation seems implausible given that all questionnaires measured lower quality of life
values than the values of a "healthy" population and therefore appear to be sensitive for
the impact of chronic sinusitis on quality of life.
The results of this quality of life investigation were in line with the examination of the
clinical end points of the trial. These clinical end points were defined as complete clinical
response, partial clinical response, no clinical response, clinical deterioration and
indeterminate. The differences in scores between the placebo group and the filgrastim
group at this 5 point scale where not statistically significant.
Frequently, an unexpected high number of missing responses plague clinical trials. This
difficulty is often held responsible for the lack of significant differences. In the current
trial, the non-response was extremely low. Furthermore, the quality of the response was
very good, only a minimal number of questionnaires were unusable. This high quality of
the response supports the conclusions of the trial.
The anticipated number of patients in this trial was based on practical considerations,
instead of a power analysis of the quality of life measures. One could speculate that the
number of included patients is just not high enough to demonstrate significant
differences. Nevertheless, on the basis of the observations in the current trial, the effect
sizes can only expected to be modest. So before discussing the opportunities associated
with more observations, the moderate effect of filgrastim in this patient population
should be considered.
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We were the first to use both the generic SF-36, the EuroQol and the McGill Pain
questionnares in chronic sinusitis patients undergoing a drug regimen. Although the SF-
36 has been used in chronic sinusitis patients undergoing endoscopic sinus surgery, most
quality of life research in chronic sinusitis patients is based on disease specific
questionnaires. Particularly our application of the SF-36 and the EuroQol in these
patients enables a comparison with scores of the general population. Figure 1 and 2
clearly indicate that the difference of the quality of life scores between chronic sinusitis
patients and the general population is noticeable. This implies that large health
improvements can be gained in these patients. As the costs of the regular antibiotic
treatment are still at a relative low level, additional investments in this patient group have
high chances of being cost-effective.
The conclusions above are of course only valid for the population of patients included in
this trial. It could well be that other patients groups or subpopulations might benefit
more from the treatment of filgrastim. This investigation gives some indications that
such patient groups indeed exist. It was found that the power of the investigation
increased when the clinical interpretation of the patient's response was included in the
analysis. This means that the clinicians were able to determine a subpopulation in which
filgrastim had better effects. It would be interesting to explore this observation more
thoroughly, as it might open the way to a more effective administration of filgrastim in
patients with chronic sinusitis.
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COSTS OF FILGRASTIM® (G-CSF) TREATMENT IN PATIENTS
WITH PERSISTENT CHRONIC RHINOSINUSITIS
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Introduction
Chronic sinusitis can be disabling and it can cause long-term reduction of quality of life.
Patients need to be treated with repeated anti-infective therapy and many chronic
sinusitis patients undergo a number of surgical procedures. Functional endoscopic sinus
surgery has been reported to offer substantial relief of chronic sinusitis in 80% of the
patients (Beam et al., 1992; Chow et al., 1992). This leaves a substantial number of
patients who do not respond to therapy with documented efficacy. Research results
suggest that some chronic sinusitis patients who do not respond to regular treatment
might benefit from filgrastim (vd Merwe & Hooijkaas, 1994). The additional costs of
filgrastim might be compensated by savings, if regular treatment is reduced.
Furthermore, if the productivity of the patient is increased by the filgrastim
administration, additional savings may occur. To test this hypothesis, we performed a
randomized clinical trial in which the costs of filgrastim (r-met-HuG-CSF) treatment in
patients with chronic sinusitis are analyzed for a 24-week interval.
The costs during the trial were expected to be driven by a large amount of protocollary
prescribed diagnostic tests and protocollary scheduled outpatient visits. Due to the trial
protocol, only little variance in costs probably occurs, since most procedures are
prescribed protocollary and therefore show more or less the same average numbers. In
order to estimate the difference with the costs of "real practice", we also performed a
cost analysis of the 24-week period before trial inclusion. This second analysis gives
information about "regular costs" of chronic sinusitis patients undergoing antibiotic
treatments, without costs that are driven by the trial protocol.
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Materials and methods
Patients and treatment
This study was performed as a double blind two-arm placebo controlled randomized
trial. Patients were registered at T-4 for a pre-treatment observation of 4 weeks before
being randomized. Between June 1995 and November 1997, 59 patients were
randomized in the trial at the Eramus Medical Centre Rotterdam (35), the University
Medical Centre Utrecht (19) and the University Hospital Nijmegen (5). Only patients
with symptoms lasting for more than 6 months were included in order to cover the
group of severe chronic bacterial sinusitis patients. The included patients had been given
all conventional treatments, such as antibiotics, nasal decongestants, functional
endoscopic sinus surgery, frontal sinus surgery and Caldwell-Luc procedures, yet they
still suffered from their disease as the treatments were unsuccessful. Patients were
included when no indication for surgical interventions of any kind to improve the
chronic sinusitis was found.
After randomization (official study entry at T0), all patients were treated with a
combination of Ciprofloxacin 750mg once a day and Clindamycin 600 mg 3 times a day
for 14 days. Patients were randomized to Filgrastim 300 µg subcutaneously (s.c.) or
placebo s.c. once a day for the first 14 days (until T2) and for another 10 weeks (until T12)
with either Filgrastim 300 µg s.c. or placebo s.c. on alternate days. After this treatment
period, patients were followed for another 12 weeks until T24 (post treatment observation
period).
Costs during the trial
In this cost analysis, the societal perspective was taken (Drummond et al., 1997). This
means that direct medical costs (costs of health care consumption) as well as indirect
costs (costs of lost production due to a disease) were calculated.
Direct medical costs consisted of the costs of all medical procedures performed in the
hospital and the costs of prescribed medication. Data concerning performed procedures,
prescribed medication, outpatient visits, hospital days, performed laboratory services and
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diagnostic procedures were recorded on the case registry forms (CRFs) and in the
hospital information system
Cost prices were based on 1996 data from the University Hospital Rotterdam and the
University Hospital Utrecht. To determine full costs, the method of absorption costing
was followed, which implies that not only costs of direct measurable units were
determined, but "non-measurable" costs (e.g. overhead) are accounted for as well
(Horngren, 1991). Using this method of absorption costing, the costs of an
otorhinolaryngology hospitalization day were Euro 221 (of which 43% personnel costs,
10% material costs and 47% overhead costs). The price of a visit to the
otorhinolaryngology outpatient clinic was Euro 86 (54% personnel costs, 5% material
costs and 41% overhead costs), whereas the price of performing a CT-scan of the sinus
was Euro 169 (32% personnel costs, 21% material costs and 47% overhead costs). Costs
of laboratory services and diagnostic procedures are based on Dutch tariffs, since they
match well with the concerning full costs. Costs of medication were determined with
prices mentioned in the "Pharmaceutical Compass 1996" (vd Kuy, 1996).
Indirect costs of chronic sinusitis were estimated according to the friction cost method
by Koopmanschap and Rutten (1996). Compared to traditional methods of calculating
costs of productivity losses, this methods assumes that the initial production level will be
gradually restored when the patient is absent (Drummond et al., 1997). Within this
method, a value of a lost production day is specified to age and gender of the patient.
Information on the time absent from work was collected by the Health and Labour
questionnaire on T-4, T0, T2, T4, T12 and T24 (Van Roijen et al., 1996). One of the items in
this questionnaire aimed to measure the number of days the patient was impeded to do
paid work due to chronic sinusitis during the last 14 days. For each time interval, the
total number of days absent from work was determined on the basis of this question.
Costs before the trial
To estimate costs of "real practice" we analyzed the costs of a 24-week period before the
trial in which a regular treatment was administered (T-28-T-4). We choosed to end the
"before trial" period at T-4, since the period T-4-T0 was used to determine the eligibility of
patients with the trial criteria, for which additional diagnostic tests were performed.
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We used the data of the patients treated in the University Hospital Rotterdam (n=35) to
determine "real practice costs" since these data were easily accessible. Data were selected
by using the hospital information system. Data concerning the medication described
from T-28-T-4 were collected by the pharmacists of the patients, after 33 patients gave
informed consent to collect these data. Twenty-six pharmacists provided the requested
data. Indirect costs were not determined for this interval, since the required information
could not be measured retrospectively.
Statistical analysis
Costs per patients were entered into the statistical software package SPSS for Windows
(release 9.0.0) and analyzed by Mann-Whitney testing. A significance level of 5% was
used.
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Results
Of the 59 randomized patients, 3 were excluded from the analysis. One of them turned
out to have cystic fibrosis, one stopped because of pain in the bones and one was
mistakenly randomized before the bacterial infection was confirmed. The remaining 56
patients were randomized to the filgrastim group (25, of which 8 males and 17 females)
and the placebo group (31, of which 18 males and 13 females). The mean age in the
filgrastim group was 45 years, whereas it was 42 years in the placebo group (p > 0.05).
Direct medical costs during the trial
In Table 1, the total direct costs of the treatment period (T0-T24) were presented. The
only significant result was the difference in total treatment costs including filgrastim
(P=0.00). In the filgrastim group, the costs of the study medication determined 64% of
the total treatment costs. Without the costs of the study medication, costs between the
study groups did not differ (see Figure 1).
Table 1. Total average direct costs per patient from T0 to T24 in Euros on the 1996 price level [median,
95% confidence interval].
Cost item filgrastim (n=25) placebo (n=31) total (n=56)
Hospital days 136 0; -144-417 0 0; 0-0 62 0; -62-187
Outpatient visits 746 686; 677-814 739 686; 709-769 742 686; 708-776
Diagnostic tests 1567 1672; 1468-1666 1561 1638; 1487-1635 1564 1655; 1506-1623
Medication 336 265; 216-456 351 382; 270-432 344 297; 276-412
Total direct costs 2785 2650; 2321-3250 2651 2665; 2560-2742 2712 2652; 2502-2923
Filgrastim 4899 5228; 4522-5277 0 0; 0-0 2235 0; 1561-2909
Total direct costs
including filgrastim 7685 7868; 7064-8306 2651 2665; 2560-2742 4947 2944; 4221-5673
Except for the costs of filgrastim, the main treatment costs consisted of the costs of
diagnostic tests (accounting for approximately 41% of the total costs when the costs of
filgrastim are excluded). This cost item contained laboratory services, biopsies and sinus
scopes.
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During the trial, patients were rarely admitted to the hospital: patients in the filgrastim
group were averagely 0.61 days hospitalized and patients in the placebo group had 0.00
hospital days (averagely 0.28 in the entire group). The patients had on average 8,65
outpatient visits in the filgrastim group and 8.57 visits in the placebo group (averagely
8.61 in the entire group). Seven of these visits were planned protocollary at forehand, the
remaining visits are supplemental visits.
Indirect costs during the trial
For each patient in the study group, the value of a lost production day was determined
according to age and gender. Subsequently, these amounts were multiplied by the
number of days on which the patients were absent from work due to chronic sinusitis.
Account was given for the fact that not every study subject performed paid labour. The
average number of absence days and the average costs of lost production are reported in
Table 2.
Table 2. Average number of days absent from work and costs of lost production in Euros on the 1996
price level due to chronic sinusitis.
Time interval filgrastim (n=25) placebo (n=31) total (n=56)
number of
absence days
costs of lost
production
number of
absence days
costs of lost
production
number of
absence days
costs of lost
production
T0-T2 0.46 16.10 1.54 108.00 1.06 66.97
T2-T4 1.00 26.60 1.50 105.39 1.28 70.22
T4-T12 0.00 0.00 5.29 360.27 2.93 199.44
T12-T24 2.08 130.55 5.14 337.25 3.77 244.97
Total: T0-T24 3.54 173.25 13.47 910.91 9.04 581.60
Although the result presented in Table 2 may suggest a difference between the filgrastim
and the placebo group, the difference is not significant due to a relative small numbers of
patients performing paid labour in both group (in both groups 50%). Besides, the total
indirect costs are distorted by the greater proportion of females in the filgrastim group
(68% as compared to 42% in the placebo group) for whom the fixed values of lost
production days are lower than for males in the friction cost method. There was no
significant age difference between the two groups which might distort the calculation of
indirect costs.
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Direct medical costs before the trial
Table 3 compares the trial costs to the costs of a 24-week interval preceding the trial
inclusion. These costs can be considered as the regular antibiotics treatment. Again, the
total costs are mainly determined by the costs of diagnostic procedures (31%). Costs
during the trial (excluding filgrastim) are approximately 3 times higher than the costs
before the trial. The only exception are costs of hospitalization, which were higher before
the study inclusion (p=0.00). Patients were hospitalized for averagely 1.22 days in the 24-
week interval preceding the trial inclusion (95% CI: 0.48-1.97). Costs of outpatient visits,
diagnostic tests, medication and total costs were significantly higher during the trial
period (p = 0.00). Patients had on average 1.63 otorhinolaryngology outpatient visits in
the period before the trial inclusion (95% CI: 1.44-1.83).
Table 3. Average costs per patient during the trial (T0-T24) compared to regular treatment costs in a 24-
week interval (T-28-T-4) in Euros on the 1996 price level [median, 95% confidence interval].
Cost item Costs during trial (T0-T24; n=56)
costs of filgrastim are excluded
Costs before trial (T-28-T-4; n=35)
"regular antibiotics treatment"
Hospital days 62 0; -62-187 270 0; 106-435
Outpatient visits 742 686; 708-776 141 158; 124-157
Diagnostic tests 1564 1655; 1506-1623 268 257; 241-296
Medication 344 297; 276-412 180 181; 155-205
Total direct costs 2712 2652; 2502-2923 859 626; 666-1054
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Discussion
In this cost analysis concerning the treatment of patients with chronic bacterial sinusitis
with filgrastim, there were no significant differences in costs between the filgrastim
group and the placebo group when the costs of filgrastim (Euro 4899) are left out of
consideration. On average, the total 24-week direct health care costs (hospitalization,
outpatient visits, diagnostic tests and medication, excluding filgrastim) were Euro 2712.
It could be claimed that the power of the analysis is restricted by the strict trial protocol:
only little variance in costs was possible as nearly all diagnostic tests and outpatient visits
were scheduled in advance. The costs of protocollary diagnostic tests were the most
important cost item, except from the filgrastim costs. Additional hospital days and
outpatient visits and additional diagnostic tests only occured rarely. For these reasons,
savings from filgrastim treatment can hardly be expected within the trial setting.
A drawback of cost studies that are conducted alongside a clinical trial like the current
analysis is the restricted focus of the research question. Only patients with symptoms
lasting for more than 6 months were included to ensure that only patients with severe
chronic bacterial sinusitis entered the trial. Besides, the included patients had already
been given all conventional treatments. Filgrastim probably may have different effects in
patients who have not been given other treatments before, as they may be expected to be
more sensitive for the treatment.
However, this study comprises the first analysis of full micro-economic costs in chronic
sinusitis patients based on real cost prices. Gliklich and Metson (1998) have calculated
micro-economic costs, but they mainly make a comparison of sinusitis medication costs
before and after surgery. Their calculations of hospital expenditures are not comparable
to our calculations, since they only used reimbursement tariffs for estimation of the
costs, instead of full prices based on real hospital costs. Ray et al. (1999) only make an
estimation of the total yearly macro-economic burden of sinusitis, but did not calculate
micro-economic costs of specific treatments.
We additionally analyzed such full micro-economic costs during a regular antibiotics
treatment of chronic sinusitis patients, since it was expected that the health care
consumption of the patients might decrease during the trial when a protocollary
outpatient visit was planned in the short run. It was hypothesized that patients who
would normally visit the outpatient clinic immediately with specific troubles now waited
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for the next protocollary visit. However in the end, just because of these protocollary
scheduled visits, the total number of outpatient visits during the trial (8.61) turned out to
be much higher than the average number of visits during a regular 24-week interval
(1.63). Therefore, the total health care costs during the trial (Euro 2,712) were
approximately three times higher than the costs during a regular antibiotics regimen
(Euro 859; p=0.000).
Our findings indicate that the administration of filgrastim does not result in a decrease of
all other health care costs, neither could a difference in indirect costs be found. Figure 1
clearly shows that the additional filgrastim costs can never be compensated by savings on
other cost items. Given the relative high costs of the filgrastim administration as
compared to a regular antibiotics treatment, the cost-effectiveness of the filgrastim
treatment would only be favourable if the additional costs were justified by a major
clinical improvement of chronic sinusitis patients or a major advance in the experienced
quality of life.
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Figure 1. Total 24-week direct costs during the trial (filgrastim and placebo, T0-T24) and during a
regular treatment (T-28-T-4).
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